SCHEMBL1597944

SCHEMBL1597944

O=C1CC(c2ccncc2)C(c2ccccc2)=NN1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR119 Q8TDV5 5/20 0.40
PDE3B Q13370 4/20 0.40
PDE3A Q14432 4/20 0.40
PDE4A P27815 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40
PBRM1 Q86U86 1/20 0.40
GAA P10253 2/20 0.39
KMT2A Q03164 2/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8871280 0.91 KDM4E (0.46) AXLDDB1CRBNSMN1; SMN2GPR119
SCHEMBL4676078 0.86 CYP17A1 (0.41) DDB1CRBNPDE3BPDE3APDE4A
SCHEMBL16061282 0.84 MAPK8 (0.41) GPR119PDE3BPDE3APDE4APDE4B
SCHEMBL3939017 0.83 PDE3B (0.50) DDB1CRBNSMN1; SMN2GPR119PDE3B
SCHEMBL1041630 0.83 GPBAR1 (0.43) AXLSMN1; SMN2GPR119PDE3BPDE3A
SCHEMBL25395897 0.82 SIRT2 (0.46) AXLSMN1; SMN2GPR119PDE3BPDE3A
SCHEMBL22923578 0.81 CYP19A1 (0.45) AXLDDB1CRBNGPR119PDE3B
SCHEMBL26282501 0.81 NPSR1 (0.49) SMN1; SMN2GPR119PDE3BPDE3AGAA
SCHEMBL25395685 0.81 LMNA (0.40) AXLSMN1; SMN2GPR119PDE3BPDE3A
SCHEMBL1013558 0.81 GPR119 (0.38) AXLSMN1; SMN2GPR119PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3842424-B1 MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES UNIV COLUMBIA (US) 2024-12-11 EP disclosed
US-11566016-B2 MAP kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-01-31 US disclosed
US-11566016-B2 MAP kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-01-31 US disclosed
US-20220009905-A1 MAP KINASE MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY 2022-01-13 US disclosed
US-20220009905-A1 MAP KINASE MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY 2022-01-13 US disclosed
US-11149020-B2 MAP kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-10-19 US disclosed
US-11149020-B2 MAP kinase modulators and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-10-19 US disclosed
EP-3842424-A1 MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES The Trustees of Columbia University in the City of New York (US) 2021-06-30 EP disclosed
EP-3842424-A1 MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES The Trustees of Columbia University in the City of New York (US) 2021-06-30 EP disclosed
EP-3521284-B1 PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF UNIV COLUMBIA (US) 2020-12-02 EP disclosed
US-8188096-B2 Protein kinase targeted therapeutics NORTHWESTERN UNIVERSITY (US) 2012-05-29 US disclosed
US-20110166153-A1 Protein Kinase Targeted Therapeutics NORTHWESTERN UNIVERSITY (US) 2011-07-07 US disclosed
US-20110166153-A1 Protein Kinase Targeted Therapeutics NORTHWESTERN UNIVERSITY (US) 2011-07-07 US disclosed
US-7919485-B2 Protein kinase targeted therapeutics NORTHWESTERN UNIVERSITY (US) 2011-04-05 US disclosed
US-7919485-B2 Protein kinase targeted therapeutics NORTHWESTERN UNIVERSITY (US) 2011-04-05 US disclosed
US-20100016587-A1 Protein Kinase Targeted Therapeutics NORTHWESTERN UNIVERSITY (US) 2010-01-21 US disclosed
US-20100016587-A1 Protein Kinase Targeted Therapeutics NORTHWESTERN UNIVERSITY (US) 2010-01-21 US disclosed
WO-2008094208-A2 PROTEIN KINASE TARGETED THERAPEUTICS NORTHWESTERN UNIVERSITY (US) 2008-08-07 WO disclosed
US-20080051410-A1 Protein Kinase Targeted Therapeutics NORTHWESTERN UNIVERSITY (US) 2008-02-28 US disclosed
US-20080051410-A1 Protein Kinase Targeted Therapeutics NORTHWESTERN UNIVERSITY (US) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166153-A1 Protein Kinase Targeted Therapeutics MAP3K1, MAP3K6, MAPK1 AXL 1940/4885DDB1 867/4885CRBN 754/4885
US-11566016-B2 MAP kinase modulators and uses thereof MAPK1, MAP3K1, MAP3K2 AXL 1414/4885DDB1 1964/4885CRBN 1591/4885
US-11149020-B2 MAP kinase modulators and uses thereof MAPK1, MAP3K1, MAP3K2 AXL 1414/4885DDB1 1964/4885CRBN 1591/4885
US-20100016587-A1 Protein Kinase Targeted Therapeutics MAP3K1, MAP3K6, MAPK1 AXL 1940/4885DDB1 867/4885CRBN 754/4885
US-20220009905-A1 MAP KINASE MODULATORS AND USES THEREOF MAPK1, MAP3K1, MAP3K2 AXL 1414/4885DDB1 1964/4885CRBN 1591/4885
US-20080051410-A1 Protein Kinase Targeted Therapeutics MAP3K1, MAP3K6, MAPK1 AXL 1940/4885DDB1 867/4885CRBN 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.